Nam Sang-do, CEO: “Miso Information Technology Connecting Healthcare and AI Targets General KOSDAQ Listing Next Year”

“Medical data cannot be handled with simple IT technology. The language of medical professionals and the language in which AI operates must be connected—and Miso Information Technology has a clear competitive edge in bridging these two worlds.”

Nam Sang-do, CEO of Miso Information Technology, shared this perspective during an interview with Edaily on the 21st at the company’s research institute in Yeoksam-dong, Gangnam-gu, Seoul. Nam is a founding member of Miso Information Technology and has led the commercialization of its data platform business for more than 20 years, serving in key roles including CTO and COO before being appointed CEO in July.

Miso Information Technology recently launched Actify AGENTIC, an AI agent management solution, following its multimodal data platform SmartBIG. The company has developed capabilities to process a wide range of multimodal medical data—including electronic health records (EHR), personal health records (PHR), wearable data, health checkup results, signal data, and biosignals—along with AI technologies designed to operate on this data in a structured and reliable manner.
Agentic AI refers to AI systems capable of autonomous judgment and action, a trend that has recently gained significant traction across the global AI industry.

Medical expertise as the foundation of AI capability

A distinctive feature of Miso Information Technology is the presence of former medical professionals—such as doctors and nurses—among its executives and employees. “We actively recruited medical professionals because domain expertise is essential for growing our healthcare business,” Nam explained. “They are directly involved in data modeling, workflow design, and AI labeling.”

Without clinical expertise, handling unstructured medical data such as EHRs would have been extremely challenging, he noted. “Because our technology is built on the real-world experience of professionals who understand clinical environments, we can process medical data more accurately and efficiently.”

Nam recalled that one of the most difficult challenges in the early stages of the healthcare data business was communication with medical staff. “IT terminology and medical terminology often felt like completely different languages,” he said. “Accurately understanding clinical intent is critical—any misunderstanding can have serious consequences.”

Phenom data and federated learning for precision healthcare

Building on this foundation, Miso Information Technology is jointly developing prediction models for major chronic diseases using phenom data from 1.5 million individuals, in collaboration with Samsung Electronics and Gangbuk Samsung Hospital. The initiative focuses on improving early diagnosis and prediction accuracy for conditions such as obesity, metabolic liver disease, hypertension, and diabetes.

Phenom data refers to physiological and biological characteristics derived from personal activity data and environmental interactions, combined with genetic factors. By integrating diverse data points—including lifestyle and behavioral patterns—it enables a more comprehensive understanding of individual health conditions.

In particular, phenom data excels at quantifying “everyday health patterns” that are difficult to capture through genetic or clinical test data alone. For example, combining real-time lifelog data—such as sleep, activity levels, heart rate variability, dietary habits, and stress indicators—with hospital clinical data enables personalized disease risk assessment.
Miso Information Technology is strengthening its research and analytical capabilities by integrating distributed PHR and EHR data through federated learning, allowing collaborative model development while maintaining data privacy.

Differentiation in a competitive global platform market

Global players such as OpenAI, Palantir, Snowflake, and Databricks are competing aggressively in the multimodal data platform market. In this landscape, Nam emphasized Miso Information Technology’s end-to-end approach as a key differentiator.

“Our platform supports the entire pipeline—from data collection and quality management (MDQ), to AI-based operational automation (AIOps), ontology modeling, retrieval-augmented generation (RAG), and agent execution—all within a single platform,” he said. “Most competitors focus on analytics or AI utilization, but lack capabilities in data ingestion and quality control. We manage data quality from the moment data enters the system.”

The MDQ solution continuously monitors data quality, detecting missing values, duplication, and errors in real time, and automatically diagnosing issues so customers can improve data reliability independently. “It’s not just about making data usable—it’s about ensuring data is managed properly from the start,” Nam added.

Global expansion and IPO outlook

Miso Information Technology is preparing for global expansion, with a particular focus on Europe and Central Asia. “We are actively preparing to enter the European market, where interest from overseas bio companies is increasing,” Nam said. “Central Asia is another strategic region, where we plan to enter through official development assistance (ODA) projects.”

Founded in 2006, Miso Information Technology will mark its 20th anniversary next year. The company has recently accelerated preparations for an IPO by appointing NH Investment & Securities as its lead underwriter and promoting Nam, formerly COO, to CEO in July. Founder and former CEO Ahn Dong-wook has assumed the role of Chairman of the Board, focusing on long-term strategy and corporate direction.

The company is targeting a general KOSDAQ listing, rather than a technology-special listing, reflecting confidence in its business fundamentals. While Nam did not disclose specific financial figures, he noted that performance has improved compared to the previous year.

“An IPO should ultimately benefit investors,” Nam said. “Our goal is not to raise excessive expectations, but to achieve a fair valuation and continue delivering value even after listing.”

https://www.edaily.co.kr/News/Read?newsId=02988086642401800&mediaCodeNo=257&OutLnkChk=Y